Advanz Pharma’s lanreotide 60 mg/0.5 ml, 90 mg/0.5 ml, and 120 mg/0.5 ml solution for injection pre-filled syringes are unavailable until at least the end of June 2026. New patient referrals for Advanz Pharma’s lanreotide 60 mg/0.5 ml, 90 mg/0.5 ml, and 120 mg/0.5 ml solution for injection pre-filled syringes will not be accepted during this period. Ipsen’s lanreotide (Somatuline Autogel®) 60 mg/0.5 ml, 90 mg/0.5 ml, and 120 mg/0.5 ml solution for injection pre-filled syringes remain available and can support increased demand. Ipsen’s lanreotide (Somatuline Autogel®) pre-filled syringes are available via an Ipsen manufacturer-sponsored homecare scheme through specific homecare providers.